NCT05166382 - Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions

Type 2 DiabetesCardiovascular Diseases

Interventions

BEHAVIORAL

Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)

Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.

BEHAVIORAL

Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)

Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.

Trial Locations (1)

80045

Aanchal Gupta, Aurora

All Listed Sponsors

collaborator

SomaLogic, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER